Healthcare: Is Biogen A Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger On the Rocks?


Manage episode 230145914 series 2394758
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.

Check out more of our content here:

1391 episodes available. A new episode about every day averaging 28 mins duration .